SLS
SELLAS Life Sciences Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.49
+5.11%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- 306.85x
- P/S forward
- 58.63x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 15.39x
- Price / sales
- —
- Price / cash flow
- -74.53x
Enterprise value
- Enterprise value
- $2.0B
- EV / sales
- —
- EV / EBITDA
- -78.05x
- EV / EBIT
- -56.24x
- Market cap
- $2.1B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026